The aim of this study was to investigate the influence of high-dose cytosine arabinoside (HDAC)-containing treatments followed by autologous hematopoietic stem cell transplantation on the survival of patients with mantle cell lymphoma.
Material and methods
The data of 27 MCL patients who were followed-up between January 2009 and December 2015 were analyzed retrospectively.
Results
The median age of the patients was 63 (range, 45–82) with 22 (81.4%) males and 5 (18.6%) females. Eight of 27 patients were treated with HDAC-containing regimens either as induction or salvage chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT). The patients who received HDAC-containing regimen followed by AHSCT were found to have better one-year survival compared to others (p = 0.03). Median follow-up of patient cohort was 27.6 months and median overall survival (OS) was not reached. The probability of one-year OS for all patients was 76.8%.
Conclusion
Our findings suggest that HDAC treatment followed by AHSCT seems to provide the best outcome for young-fit patients presenting with mantle cell lymphoma.
SwerdlowSHCampoEHarrisNL, et al.WHO classification of tumors of the haematopietic and lymphoid tissues, Lyon, France: IARC, 2008.
2.
Non-Hodgkin’sLymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group. Blood1997; 89: 3909–3918.
3.
VoseJM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol2015; 90: 739–745.
4.
VoseJM. Mantle cell lymphoma: 2013 Update on diagnosis, risk stratification and clinical management. Am J Hematol2013; 88: 1082–1088.
5.
HerrmannAHosterEZwingersT, et al.Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol2009; 27: 511–518.
6.
MartinPChadburnAChristosP, et al.Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol2008; 19: 1327–1330.
7.
VandenbergheERuiz de ElviraCLoberizaFR, et al.Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol2003; 120: 793–800.
8.
DreylingMLenzGHosterE, et al.Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood2005; 105: 2677–2684.
9.
De GuibertSJaccardABernardM, et al.Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica2006; 91: 425–426.
10.
VoseJLoberizaFBiermanP, et al.Mantle cell lymphoma (MCL): induction therapy with Hyper CVAd/High dose and cytarabine (M-C)(+-rituximab) improves result of autologous stem cell transplant in first remission. J Clin Oncol2006; 24: 7511–7511.
11.
VigourouxSGaillardFMoreauP, et al.High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica2005; 90: 1580–1582.
12.
EvensAMWinterJNHouN, et al.A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol2008; 140: 385–393.
13.
GeislerCHKolstadALaurellA, et al.Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood2008; 112: 2687–2693.
14.
RomagueraJEFayadLRodriguezMA, et al.High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol2005; 23: 7013–7023.
15.
GianniAMMagniMMartelliM, et al.Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood2003; 102: 749–755.
16.
DelarueRHaiounCRibragV, et al.CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood2013; 121: 48–53.
17.
LossosISHoseinPJMorgenszternD, et al.High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAMT), a modification of the National Cancer Institute 89-C-41 regimen, in patients with newly diagnosed mantle cell lymphoma. Leuk Lymphoma2010; 51: 406–414.
18.
Hermine O, Hoster E, Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net) [abstract]. In: Proceedings of the 54th ASH annual meeting and exposition, Atlanta, GA, December 9–11 2012. Washington (DC): American Society of Hematology. [Abstract Nr:151].
19.
ListerTACrowtherDSutcliffeSB, et al.Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol1989; 7: 1630–1636.
20.
HermineOHosterEWalewskiJ, et al.Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) ıncreases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the European mantle cell lymphoma network (MCL net). Blood2012; 120: 151–151.
21.
LenzGDreylingMHosterE, et al.Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospectiverandomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol2005; 23: 1984–1992.
22.
KhouriIFRomagueraJKantarjianH, et al.Hyper-CVAD and high-dose metothrexate/cytarabine followed by stem cell transplantation: an active regimen for mantle cell lymphoma. J Clin Oncol1998; 16: 3803–3809.
23.
KhouriIFSalibaRMOkorojiGJ, et al.Long-term follow-up of autologous cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer2003; 98: 2630–2635.
24.
ViscoCFinottoSZambelloR, et al.Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol2013; 31: 1442–1449.
